Singapore, July 6 -- University College London (UCL) and Japanese pharma firm Eisai have signed a new agreement to extend their long-standing collaboration in drug discovery and development for five more years, taking the partnership through to 2030. This alliance reinforces a unique model built on trust, combining academic excellence with industry expertise to accelerate innovation in neuroscience drug discovery, investigating new ways of treating neurodegenerative diseases such as Alzheimer's, Parkinson's, Amyotrophic Lateral Sclerosis and other related disorders.

One of the most notable outcomes of the UCL-Eisai collaboration to date is the anti-MTBR tau antibody E2814, which was first discovered as part of collaborative research betw...